Latham & Watkins Advises on Alto Neuroscience’s Initial Public Offering

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) has announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of US$16 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately US$128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto. In addition, Alto has granted the underwriters a 30-day option to purchase up to an additional 1,206,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Alto.

Latham & Watkins LLP advises the underwriters in the offering, with a capital markets team led by New York partner Nathan Ajiashvili, Chicago partner Christopher Lueking, and Orange County/ Bay Area partner Ross McAloon, with New York associates Danny Shulman and Ilan Lavian, and Orange County associate Caitlin Nguyen.